Last updated: July 12, 2026

Executive summary: Fioricet with Codeine is a branded, combination analgesic (butalbital/acetaminophen/caffeine + codeine) with limited, highly regulated growth potential in the U.S. market due to opioid scheduling and substitution pressure from generics and alternative non-opioid headache therapies. Financial trajectory is constrained by (1) a mature category with broad generic availability, (2) FDA risk controls for opioid-containing products, and (3) payer and prescriber migration toward non-opioid migraine and tension-headache options. Market dynamics increasingly hinge on opioid risk management, label/treatment guideline alignment, and competitive displacement by newer branded and low-cost non-opioid therapies.

How fast is Fioricet with Codeine declining in U.S. sales?

Featured snippet answer: The product sits in a declining, mature analgesic niche where market share erosion tends to be structural rather than cyclical, driven by generic substitution and opioid-related prescribing constraints.

U.S. demand drivers specific to this combination

Fioricet with Codeine is used for headache-related pain where butalbital-containing products and opioid rescue are prescribed. Demand is influenced by:

Headache treatment guideline shifts toward migraine-specific therapy and non-opioid approaches for tension-type headache.
Opioid prescribing pressure tied to FDA and state initiatives on opioid risk and safer use.
Risk of medication overuse headache with barbiturate-containing regimens, which suppresses long-term use.

Constraint from “basket” utilization patterns

Combination analgesics with codeine behave like “rescue” therapies inside a larger headache spend category. When payers steer patients away from opioid-containing products, the addressable population shrinks rather than price alone compressing.

What to expect for near-term unit movement

Typical trajectory for mature branded combinations in this segment is:

Low unit growth or modest declines
Share retention depends on prescriber habits and patient-specific access needs
Revenue pressure follows unit pressure and net-price resets driven by competitive contracting

(Commercial trajectory must be benchmarked against publicly available sales series; without specific numeric sales filings here, the analysis focuses on structural drivers and risk timing.)

What market share do generics take from Fioricet w/ codeine and why?

Featured snippet answer: Generic substitution and payer preferred-formulary rules are the main share-leak mechanisms, with opioid risk oversight accelerating the switch from opioid-containing rescue products.

Structural reasons generics win in combination analgesics

Multi-ingredient generics are administratively easy to adopt because they mirror dose form and active ingredients.
Wider price access drives utilization away from branded supply in pharmacy benefit settings.
Therapeutic interchange is clinically plausible when the prescriber’s goal is short-term pain control rather than migraine-specific disease modification.

Payer and pharmacy benefit dynamics

For opioid-containing analgesics:

Plans often apply step therapy or prior authorization (even when not legally required).
Many prefer non-opioid analgesics and limit codeine-containing options to defined scenarios.

Prescriber switching behavior in headache

Headache is a high-frequency condition where physicians respond quickly to:

guideline updates,
adverse-event risk signals,
institutional stewardship policies,
local formulary changes.

How do opioid-related controls affect the financial trajectory of codeine-containing analgesics?

Featured snippet answer: FDA and state-level opioid risk controls depress volume growth and raise compliance friction, which typically pushes these products into a shrinking or flat-to-down commercial lane.

Where regulatory and risk controls hit revenue

Tighter prescribing controls reduce initiation rates and refill frequency.
Risk management expectations can raise the effective cost of dispensing and monitoring.
Public health scrutiny can change payer coverage policies quickly.

Category-level consequence

Even when codeine-containing products retain a niche, demand tends to be:

less elastic upward under new demand creation,
more sensitive to coverage tightening.

What exclusivity and patent cliffs determine Fioricet with Codeine’s long-term outlook?

Featured snippet answer: For mature combination analgesics, the financial future is typically dictated by whether key Orange Book-listed patents and exclusivity already expired; remaining value tends to be from brand labeling, supply reliability, and contracting rather than protected monopoly pricing.

Typical timeline mechanics that govern combination products

In practice, these products’ revenue is shaped by:

Composition-of-matter and formulation patents (if any are still in force)
Method-of-use or use-related patents (if tied to headache treatment strategies)
Regulatory exclusivities linked to changes in NDA conditions or new dosage forms (rarer for old products)

How to read “cliff risk” in this product category

For combination analgesics with codeine, cliff timing is often “already occurred” in commercial datasets due to:

long market history,
early generic entrants,
broad competition.

Because this prompt requires a complete, accurate response and does not provide the NDA number, label strength, or Orange Book listings to anchor specific expiration dates and patent numbers, numeric cliff mapping cannot be produced here.

What does FDA status imply for generics and potential new entrants?

Featured snippet answer: For mature opioid-containing combination analgesics, FDA approval pathways are typically already occupied by multiple generic competitors, limiting brand pricing power and reducing incremental entry risk.

Likely FDA pathway realities for a mature product

If the brand NDA is old and key patents have expired, generics can often rely on ANDA approvals without needing litigation.
If formulation or method patents still exist, entrants face Paragraph IV litigation or delayed launches.

What matters commercially

Number of competing ANDA products: more products usually means faster net-price pressure.
ANDA supply stability: shortages can temporarily improve price and volume for the brand, but this is episodic.

What patent estate protects Fioricet with Codeine, and how strong is it?

Featured snippet answer: Patent strength in mature combination analgesics usually provides limited incremental protection because key barriers tend to be structural (active ingredient + dose form already genericized), not surmountable solely by avoiding one formulation detail.

What a “strong” estate would need here

For a meaningful barrier to generic competition to persist, the brand would need:

active patents listed in the Orange Book that cover the commercial formulation or method-of-use,
enforceable claim scope that generics must design around,
a litigation history that discourages entry.

This analysis cannot enumerate specific patents, claim scope, assignees, or expiration dates without Orange Book data tied to this product’s NDA.

How do generic entry risks play out for codeine/butalbital/acetaminophen/caffeine combos?

Featured snippet answer: Generic entry risk is mostly already realized; remaining risks typically come from label changes, formulation/strength variants, and supply reshuffling rather than first-time generic launch.

Typical entry channels

Full generic substitution when patents/exclusivity expire.
Launch of additional strengths if the brand covers a smaller subset of market SKUs.
Interchange based on PDL or therapeutic equivalence once coverage rules shift.

Litigation as a second-order driver

Where litigation still occurs, it usually determines:

timing of specific ANDA launches,
settlement-driven “at-risk” outcomes.

A full Paragraph IV and settlement map requires NDA-specific litigation records and Orange Book patent-by-patent status, which is not included in the prompt.

How does Fioricet with Codeine compare with other headache analgesics on reimbursement and utilization?

Featured snippet answer: Non-opioid analgesics and newer headache-specific therapies typically carry better payer alignment, pushing Fioricet with Codeine toward lower utilization and more constrained coverage.

Competitive set to model in forecasting

NSAIDs and acetaminophen-based regimens (lower risk, broad coverage)
Migraine-specific classes (CGPR antagonists, triptans, and other modern options depending on indication and formulary)
Butalbital-free options (lower barbiturate risk)
Other opioid rescue options with different payer thresholds

Reimbursement and formulary outcomes

In many plans, codeine-containing options are:

restricted to limited diagnoses,
subject to utilization management,
less preferred relative to safer alternatives.

What commercial metrics should investors track for Fioricet with Codeine?

Featured snippet answer: Track net sales and prescription counts together with wholesaler inventory and state/federal opioid policy changes to separate demand decline from supply or contract effects.

Metrics that move quarterly results most often

NDC-level prescriptions (volume signal)
Net sales per unit (pricing and rebate pressure)
Wholesaler buying patterns (inventory stocking and channel pull-through)
Share-of-voice in pharmacy claims (formulary impact)
PA/prior authorization rates for opioid-containing analgesics in major PBMs (policy proxy)

What to infer from metric combinations

Declining prescriptions with stable net price signals coverage restriction.
Declining net sales with stable prescriptions suggests contract repricing.
Spikes in wholesaler inventory with flat prescriptions suggests distribution-driven events.

Key risks and upside scenarios for Fioricet w/ codeine financial performance

Featured snippet answer: Downside is primarily policy and substitution driven; upside is episodic supply/shortage or formulary reversals, which are hard to sustain.

Downside risks

Continued payer restriction on opioid-containing headache agents
Further clinical guideline tightening around barbiturate use in headache
Sustained generic competitive pressure on net price
Adverse event scrutiny increasing compliance burden

Upside possibilities

Supply constraints among competitors leading to temporary brand pull-through
Contracting changes that improve net price
Expanded use in a narrow patient subpopulation where alternatives fail or are contraindicated

Key Takeaways

Fioricet with Codeine’s financial trajectory is structurally constrained by generic substitution and opioid-related prescribing controls, making sustained volume growth unlikely.
Market dynamics are dominated by payer coverage and prescriber guideline alignment, not promotional elasticity.
Long-term value depends on whether any Orange Book-listed, enforceable protections still exist for specific formulations or method-of-use claims. Without NDA-linked patent and exclusivity data, cliff timing and patent strength cannot be quantified here.
Near-term performance should be modeled through prescription trends, net price per unit, wholesaler inventory, and opioid policy changes that affect utilization management.

FAQs

Does Fioricet with Codeine face major “new generic launch” risk or is competition already mature?
How do state opioid prescribing laws typically change the prescribing volume of codeine-containing analgesics?
What formulary levers most often reduce utilization of opioid-containing headache rescue products?
What NDC-level metrics best indicate whether a brand like Fioricet with Codeine is losing share versus losing price?
How do shortages of generic codeine combinations affect short-term brand revenue and inventory dynamics?

References (APA)

U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
U.S. Food and Drug Administration. (n.d.). Drug Approval Reports and Databases.

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	FIORICET W/ CODEINE at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actavis Labs Ut Inc	FIORICET W/ CODEINE	acetaminophen; butalbital; caffeine; codeine phosphate	CAPSULE;ORAL	020232-001	Jul 30, 1992	AB	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

AI Deep Research

Questions you can ask:

Summary for FIORICET W/ CODEINE